NEWTOWN SQUARE, Pa., June 16, 2014 /PRNewswire/ -- Kibow Biotech, Inc., an internationally-recognized research company, and winner of a 2014 BIO International Convention "Buzz of BIO Award", is the first biotechnology company specializing exclusively in dietary supplement products to receive the honor during BIO's 29-year history. BIO is the world's largest trade association, representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and more than 30 other nations. BIO member companies are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.
Dr. Natarajan Ranganathan, Kibow Biotech's co-founder and Chief R&D Scientist says, "The decade of research efforts on the concept of balancing the Gut Microbiome with probiotics (beneficial health impacting microbes) is finally gaining more recognition." He also added that a scientific basis and rationale for "a shift from Human Genome to Gut Microbiome" has been established only recently, and the process of using it to address various healthcare problems is just beginning. (Ref: "Health in a Pill Building the case of Supplements" the cover story April 21, 2014 Chemical and Engineering News).
Established in 1997, Kibow Biotech is a unique wellness company with scientific and R&D expertise in probiotic-based and other dietary supplements. Kibow Biotech provides the highest-quality natural solutions for customers hoping to improve their quality of life. Scientifically and clinically-validated, Kibow's wellness products provide customers with safe and effective alternatives they can trust: Renadyl, the world's best-selling probiotic for kidney health; Kibow Flora, a potent probiotic formulation for digestive and immune health; Kibow Fortis, a multi prebiotic fiber supplement for digestive health, weight control and glucose balance; Azodyl®, the natural solution for dogs and cats with kidney failure.
Dr. Natarajan Ranganathan will be presenting Kibow Biotech, Inc. and their breakthrough probiotic and prebiotic wellness supplements at the 2014 BIO International Convention, June 23-26 in San Diego, California. Kibow Biotech's recognition is the result of its earlier selection for a poster presentation, as an Emerging Biotech Company, at the 2007 BIO-Boston Meeting as well as for its novel approach to pharmaceutical-like product validation for "enteric uremic toxin reduction technology" (Enteric Dialysis®). Kibow's innovative probiotic dietary supplement, Renadyl, addresses the accumulation of various uremic toxins which diffuse into the bowel as a consequence of failing kidneys. In combination with the standard-of-care treatment for primary diseases such as diabetes, hypertension and other related conditions, Renadyl, may help delay progression to dialysis. Subject to additional clinical trials and validation, Renadyl, also possesses excellent potential to reduce the frequency or duration of dialysis, ultimately affording better outcomes and saving billions of healthcare dollars worldwide. Kibow Biotech, Inc. is looking to partner with a major international pharmaceutical or Biotech Company to advance its presence.
Forward-looking statements: This press release contains forward-looking statements reflecting management's current views of future events. These forward-looking statements include the current classification of the dietary supplement formulation, Renadyl, for kidney health in the USA and the possibility of its approval as a drug or food supplement in some other countries as per respective governmental authorities. Kibow Biotech is not a pharmaceutical company; hence, its products are not drugs and may not be considered as treatments or prevention products or therapy. The dietary supplement formulation of Renadyl will not cure, prevent or mitigate any disease. Other factors, possibly causing or contributing to differences in actual results include, but are not limited to: risks associated with any future clinical trials of product candidates; the possibility that testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators; and the Company's dependence on intellectual property. Kibow Biotech, Inc. expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.
Charles L. Carfagno, Jr.
MediaMark Spotlight, Inc.
SOURCE Kibow Biotech Inc.